Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Non-Current Liabilities (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Other Non-Current Liabilities over the past 12 years, most recently at $20.0 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $20.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $20.0 million (changed N/A YoY), and the annual figure for FY2025 was $20.0 million, changed.
  • Other Non-Current Liabilities for Q4 2025 was $20.0 million at Viridian Therapeutics, Inc.\DE, up from $2.6 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for VRDN hit a ceiling of $20.0 million in Q4 2025 and a floor of $33000.0 in Q1 2021.
  • Median Other Non-Current Liabilities over the past 5 years was $1.2 million (2021), compared with a mean of $2.4 million.
  • Peak annual rise in Other Non-Current Liabilities hit 3112.12% in 2022, while the deepest fall reached 64.26% in 2022.
  • Viridian Therapeutics, Inc.\DE's Other Non-Current Liabilities stood at $1.2 million in 2021, then fell by 2.98% to $1.2 million in 2022, then decreased by 15.61% to $989000.0 in 2023, then soared by 118.5% to $2.2 million in 2024, then surged by 826.89% to $20.0 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $20.0 million (Q4 2025), $2.6 million (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.